Brave new world revisited: Focus on nanomedicine

#1 by Lesley , Thu Dec 17, 2020 8:18 pm

Bengt Fadeel a; Christoph Alexiou b
a Nanomedicine & Nanosafety Laboratory (NNL), Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden
b Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Section for Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen, Else Kröner-Fresenius-Stiftung Professorship, 91054, Erlangen, Germany


Nanomedicine is at a crossroads: with relatively few success stories in terms of clinical translation despite more and more research on increasingly sophisticated nanomaterials, it is important to consider whether we are on the right track. Indeed, it is crucial that we address the fact that while considerable efforts are being made to overcome barriers to translation from the bench to the clinic, scientists are still struggling to decipher fundamental aspects of nanomaterial interactions with biological systems. We believe that a key to the successful adoption of nanomedicines in oncology and beyond lies in a deeper understanding of underlying biological processes and in decoding interactions between engineered nanomaterials and biological systems. Here we provide an overview of progress in nanomedicine during the past 5 years.

Full paper:

Posts: 38
Date registered 12.18.2019

Last edited 12.17.2020 | Top


Biotransformation of Food-Grade and NanometricTiO2in the Oral–Gastro–Intestinal Tract: DrivingForces and Effect on the Toxicity

Xobor Create your own Forum with Xobor